Cybin Inc. (NEO: CYBN) Files Patent Designed to Bolster IP Psychedelic Molecule, Delivery Mechanism Portfolio 

  • Company files 12th patent to strengthen proprietary IP program
  • Cybin believes treatments can decrease costs, increase access to important therapeutics
  • Patent provides wide range of benefits in Cybin’s four drug candidate program

Cybin (NEO: CYBN) (OTCQB: CLXPF) has filed a new provisional patent application designed to strengthen the company’s ongoing drug candidate programs ( Cybin, a biotechnology company focused on progressing psychedelic therapeutics, is focused on expanding its four active drug programs targeting depression, addiction and other psychiatric conditions alongside its growing portfolio of 50+ proprietary psychedelic molecules.

“By continuing to innovate in directions to enhance the patient experience and reducing clinical observation times, we believe our treatments can decrease costs and increase the capacity of medical professionals in this field, which will promote increased access to these important therapeutics for those in need,” said Cybin CEO Doug Drysdale.

According to the announcement, the patent — the 12th filed by the company— has a provisional application including disclosures directed to innovate oral dosage forms thought to provide therapeutic advantages in addressing Cybin’s target indications over the current options. The application is also synergistic with other patent applications filed by Cybin that are also related to a delivery technology covering various chemically synthesized psychedelic molecules, which is expected to provide faster onset times in a similar route to intravenous treatments.

In addition, Cybin noted that the patent application strengthens its portfolio relative to deuterated psychedelic molecules and analogues that are designed to produce greater stability, better potency, more control over duration and greater bioavailability than other forms of these molecules. Finally, the patent application disclosures related to more rapid therapeutic onset as well as reduced duration and side effects are intended to decrease the clinical costs of administration resulting from shortened clinical observation time.

Cybin filed the patent with the U.S. Food and Drug Administration, an application that reveals novel compositions intended to have improved pharmacokinetic profiles while retaining key efficacy measures of the original molecules; the application also outlines novel methods of deploying Cybin’s original compositions with more rapid therapeutic onset of the company’s psychedelic tryptamine at the same time while reducing the number and duration of psychedelic and therapeutic effects.

Cybin’s four drug programs include CYB001, a sublingual psilocybin formulation designed for patients suffering from major depressive disorder; CYB003 and CYB004, both proprietary deuterated psychedelic tryptamine designed for treatment of alcohol use disorder and other therapy resistant psychiatric disorders; and CYB005, a phenethylamine targeting psychiatry and neurology treatment.

Cybin Corp., a leading biotech company focused on progressing psychedelic therapeutics, is on a mission to revolutionize mental health care. The company is focused on progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.

For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:

BioMedWire (BMW)
San Francisco, California
415.949.5050 Office

BioMedWire is part of the InvestorBrandNetwork.


Select A Month

Official NewsWire Relationships

BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

BioMedWire Currently Accepts



Bitcoin Cash

Bitcoin Cash





USD Coin

USD Coin

Contact us: 415.949.5050